CEO Michael Weickert will present Phase 1 safety and efficacy results for zelenirstat in the Orphan Drug indication of Acute Myeloid Leukemia (AML) at the World Orphan Drug Congress USA 2024, Apr 23-25, 2024.

Pacylex initiates a Phase 2a study in colorectal cancer with the first patient dosed with the recommended Phase 2 dose (RP2D). Prolonged Stable Disease of >6 months was observed in 57% (4/7) of the solid tumor patients.

Zelenirstat disrupts oxidative phosphorylation in cancer cells at AACR 2024. This defines a second potential mechanism which may account for early signs of zelenirstat anti-cancer activity in the Phase 1 study

CEO Michael Weickert will attend the upcoming BIO CEO & Investor Conference in NYC and will be meeting with investors regarding the company's Series B funding round.

Zelenirstat shows clinical benefit for colorectal and appendiceal cancer patients in Phase 1 Phase 1 results will be presented on January 20, 2024 at the ASCO Gastrointestinal Cancers Symposium

Pacylex passes major milestones in 2023 including: Phase I completion, no DLTs up to the target drug exposure, evidence of efficacy, and launching our Phase IIa.

Pacylex Pharmaceuticals Reports Safety and Efficacy Results from Its Phase 1 First-In-Human Study of Zelenirstat (PCLX-001) Pacylex’s CEO Will Present at Two Upcoming Life Science Investment Conferences

Pacylex recently reported results at the Canadian Association of Radiation Oncology highlighting that zelenirstat was more effective than clinically used radiosensitizers